Sign in →

Apixaban Level

eD-H Order Code

LAB4092

Specimen Collection Information

Specimen Minimum Test Volume Container Special Handling
Blood

Neonatal/Pediatric
Minimum Volumes

All other Coag tubes must be filled to the line on tube.
 

 

Specimen Transport Temperature

Double spin, separate, and freeze

Specimen Stability

4 hours

Additional Specimen Instructions

1.8 mL Sodium Citrate tube filled to the line

OR

2.7 mL Sodium Citrate tube filled to the line

 

Blue top tubes must be filled within 10% of stated volume. A discard tube must be used if a citrate tube is to be drawn using a winged blood collection set. It is important to remove air from the blood collection set to ensure the proper blood volume is obtained in the coag tube.

 

If the patient has a known hematocrit >55%, please contact the coagulation lab for an adjusted collection tube before drawing the blood.

Interpretive Data

Assay Display

 Interpretive Data
Apixaban Level Apixaban  an oral anticoagulant that directly inhibits factor Xa  has been approved by the US Food and Drug Administration for prophylaxis of thrombosis in atrial fibrillation and surgical patients and treatment of venous thromboembolism (VTE). Unlike Warfarin  it does not require routine therapeutic monitoring. However  in selected clinical situations  measurement of drug level would be useful (eg  kidney insufficiency  assessment of compliance  periprocedural measurement of drug concentration  suspected overdose  advanced age  and extremes of body weight).  Therapeutic reference ranges have not been established  however  peak and trough levels observed in clinical trials at different dosing are available. Apixaban concentration may be affected by drug interactions and liver or renal disease.

 

Indication                  Dose           Trough Plasma   Peak Plasma
                                           Concentration   Concentration
                                           ng/mL           ng/mL
                                           (predose)       (postdose)*

Preventation of VTE:        2.5 mg twice    23 - 109         41 - 146
elective hip or knee        daily
replacement surgery

Preventation of stroke      2.5 mg twice    34 - 162         69 - 221
and systemic embolism:      daily
nonvalvular atrial          5 mg twice      41 - 230         91 - 321
fibrillation                daily

Treatment of DVT,           2.5 mg twice    11 - 90          30 - 153
treatment of PE and         daily
preventation of recurring   5 mg twice      22 - 177         59 - 302
DVT and PE (VTE)            daily
                            10 mg twice     41 - 353        111 - 572
                            daily

           *Peak is determined 2-4 hours postdose

CPT(s)

80299

Performing Lab Section

Hematology